Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMKX003561
- Development stage
- Preclinical
- Lead developer
- Jemincare
- Modality
- Small Molecules
01
Overview
JMKX003561 is a preclinical small molecule drug candidate being developed by Jiangxi Jemincare Group Co., Ltd. (and its subsidiary Zhejiang Hangyu Pharmaceutical) for the treatment of cancer and renal diseases. The compound is described as targeting a novel, undisclosed molecular target. Early research and pipeline listings indicate active development for indications including pancreatic cancer and nephrosis. As part of Jemincare's Small Molecule Innovation Center, it represents a first-in-class or innovative approach to these therapeutic areas, although specific mechanistic details and the identity of the biological target remain proprietary at this stage of development.
Beyond the preview
Go deeper on JMKX003561.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMKX003561.